Hidenori Sakai

6PUBLICATIONS
19CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsRegenerative medicine (incl. stem cells)Predictive and prognostic markersInternational arbitration
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 25, 2026
Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry.

|May 18, 2026
Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry.

|Feb 05, 2026
Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Hidenori Sakai, Koshiro Sonomoto, Shingo Nakayamada

|Jan 16, 2026
Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.

Masanobu Ueno, Koshiro Sonomoto, Hiroaki Tanaka

|Jan 16, 2026
Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Koshiro Sonomoto, Shingo Nakayamada, Hidenori Sakai

|Sep 17, 2024
Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.

Hidenori Sakai, Yusuke Miyazaki, Shingo Nakayamada

Pageof 1

Frequent Collaborators

6 joint publications

Shingo Nakayamada

6 joint publications

Masanobu Ueno

6 joint publications

Yoshiya Tanaka

5 joint publications

Satoshi Kubo